Secukinumab for the treatment of palmoplantar psoriasis: a 2-year, multicenter, real-life observational study

References

• Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82(3):192–195.
   PubMed Web of Science ®Google Scholar
• Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489.
   PubMed Web of Science ®Google Scholar
• Pettey A, Balkrishnan R, Rapp SR, et al. Patients with palmoplantar psoriasis have more physical disability and discomfort than patients with other forms of psoriasis: implications for clinical practice. J Am Acad Dermatol. 49(2): 271–275. 2003.
   PubMed Web of Science ®Google Scholar
• Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589.
   PubMed Web of Science ®Google Scholar
• Miceli A, Schmieder GJ. Palmoplantar Psoriasis. 2021 Aug 7. StatPearls [Internet]: Treasure Island (FL): StatPearls Publishing. [cited 2021 Dec 20]. PMID: 28846363. Available from:https://www.ncbi.nlm.nih.gov/books/NBK448142/
   Google Scholar
• Farley E, Masrour S, McKey J, et al. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–1031.
   PubMed Web of Science ®Google Scholar
• Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared to moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 71(4): 623–632. 2014.
   PubMed Web of Science ®Google Scholar
• Dopytalska K, Sobolewski P, Blaszczak A, et al. Psoriasis in special localizations. Reumatologia. 2018;56(6):392–398.
   PubMedGoogle Scholar
• Al-Mutairi A, Abdalla TO, Nour TM. Resistant palmoplantar lesions in patients of psoriasis: evaluation of the causes and comparison of the frequency of delayed-type hypersensitivity in patients without palm and sole lesions. Med Princ Pract. 2014;23(6):561–567.
   PubMed Web of Science ®Google Scholar
• Sanchez IM, Sorensen E, Levin E, et al. The efficacy of biologic therapy for the management of palmoplantar psoriasis and palmoplantar pustulosis: a systematic review. Dermatol Ther. 2017;7(4):425–446.
   PubMed Web of Science ®Google Scholar
• Sanchez IM, Sorensen E, Levin E, et al. EMA Summary of product characteristics. [cited 2021 Dec 20]. Available from:https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf
   Google Scholar
• Prinz I, Sandrock I, Mrowietz U. Interleukin-17 cytokines: effectors and targets in psoriasis – a breakthrough in understanding and treatment. J Exp Med. 2020;217(1):e20191397.
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9(1):5–21.
   PubMed Web of Science ®Google Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21(20):7488.
   PubMed Web of Science ®Google Scholar
• Aboobacker S, Kurn H, Aboud A, et al. 2021Jun29; StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021, Jan PMID: 30725776.
   Google Scholar
• Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med. 2021;21(3):170–173.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmoplantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 28(10): 1298–1305. 2014.
   PubMed Web of Science ®Google Scholar
• Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo- controlled phase II dose-ranging study. Br J Dermatol. 2013;168(2):412–421.
   PubMed Web of Science ®Google Scholar
• Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo- controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–411.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety, and usability of secukinumab administration by autoinjector/pen in psoriasis a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–1675.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2·5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 182(4): 889–899. 2020.
   PubMed Web of Science ®Google Scholar
• Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician’s global assessment. J Am Acad Dermatol. 2004;51(4):563–569.
   PubMed Web of Science ®Google Scholar
• Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): indication: for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Mar. Appendix 5, Validity of Outcome Measures.
   Google Scholar
• Papp KA, Fonjallaz P, Casset-Semanaz F, et al. Analytical approaches to reporting long-term clinical trial data. Curr Med Res Opin. 2008;24(7):2001–2008.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020;20(2):173–182.
   PubMed Web of Science ®Google Scholar
• Augustin M, Jullien D, Martin A, et al. Real-world evidence of secukinumab in psoriasis treatment – a meta-analysis of 43 studies. J Eur Acad Dermatol Venereol. 2020;34(6):1174–1185.
   PubMed Web of Science ®Google Scholar
• Rocamora V, Garcias-Ladaria J. Complete response of secukinumab in palmoplantar psoriasis. Dermatol Online J. 2017;23(10):23.
   Google Scholar
• Megna M, Cirillo T, Balato A, et al. Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs. J Eur Acad Dermatol Venereol. 2019;33(1):e22–e23.
   PubMed Web of Science ®Google Scholar
• Rompoti N, Katsimbri P, Kokkalis G, et al. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: a 104-week clinical study. Dermatol Ther. 2019;32(5):e13006.
   PubMed Web of Science ®Google Scholar